Primary refractory multiple myeloma: a real-world experience with 85 cases

被引：10

作者：

Jurczyszyn, Artur ^{[1
]}

Waszczuk-Gajda, Anna ^{[2
]}

Castillo, Jorge J. ^{[3
]}

Krawczyk, Katarzyna ^{[1
]}

Stork, Martin ^{[4
]}

Pour, Ludek ^{[4
]}

Usnarska-Zubkiewicz, Lidia ^{[5
]}

Potoczek, Stanislaw ^{[5
]}

Hus, Iwona ^{[6
]}

Davila Valls, Julio ^{[7
]}

Hari, Parameswaran ^{[8
]}

Chhabra, Saurabh ^{[8
]}

Gentile, Massimo ^{[9
]}

Mikala, Gabor ^{[10
]}

Varga, Gergely ^{[11
]}

Chim, Chor Sang ^{[12
]}

Fiala, Mark ^{[13
]}

Vij, Ravi ^{[13
]}

Schutz, Natalia ^{[14
]}

Rodzaj, Marek ^{[15
]}

Porowska, Agnieszka ^{[16
]}

Vesole, David H. ^{[17
]}

Druzd-Sitek, Agnieszka ^{[18
]}

Walewski, Jan ^{[18
]}

Nooka, Ajay K. ^{[19
]}

机构：

[1] Jagiellonian Univ Med Coll, Dept Hematol, Krakow, Poland

[2] Warsaw Med Univ, Dept Hematol Oncol & Internal Med, Warsaw, Poland

[3] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Univ Hosp, Dept Internal Med Hematol & Oncol, Brno, Czech Republic

[5] Wroclaw Med Univ, Dept Hematol Blood Neoplasms & Bone Marrow Transp, Wroclaw, Poland

[6] Med Univ Lublin, Lublin, Poland

[7] Complejo Asistencial Avila, Avila, Spain

[8] Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI 53226 USA

[9] Hematol Unit Cosenza, Cosenza, Italy

[10] South Pest Cent Hosp, Natl Inst Hematol & Infectol, Dept Hematol & Stem Cell Transplantat, Budapest, Hungary

[11] Semmelweis Univ, Dept Internal Med 3, Budapest, Hungary

[12] Queen Mary Hosp, Div Hematol & Med Oncol, Hong Kong, Peoples R China

[13] Washington Univ, Sch Med, St Louis, MO USA

[14] Hosp Italiano Buenos Aires, Dept Internal Med, Buenos Aires, DF, Argentina

[15] Reg Specialist Hosp, Dept Hematol, Krakow, Poland

[16] Cent Clin Hosp, Dept Oncol & Haematol, Minist Interior, Warsaw, Poland

[17] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[18] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[19] Emory Univ, Sch Med, Atlanta, GA USA

来源：

LEUKEMIA & LYMPHOMA | 2020年 / 61卷 / 12期

关键词：

Double-refractory multiple myeloma; prognosis; treatment response; survival; STEM-CELL TRANSPLANTATION; BORTEZOMIB PLUS DEXAMETHASONE; INTERNATIONAL STAGING SYSTEM; HIGH-RISK; INDUCTION TREATMENT; INITIAL TREATMENT; THERAPY; IMPACT; THALIDOMIDE; OUTCOMES;

D O I：

10.1080/10428194.2020.1788014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This study determined whether 85 patients with multiple myeloma (MM) double-refractory to primary induction therapy with triplet regimens had a homogenous prognosis. The overall response rate (ORR) after the second-line therapy was 51%. Patients who proceeded to immediate autologous stem cell transplantation (ASCT) had better ORR than those who received conventional therapies (62% vs. 31%). The ORR for patients who had ASCT directly after the frontline therapy was higher than for those treated with other regimens as the second line therapy (91% vs. 45%) and offered ASCT as the third-line therapy (91% vs. 55%). The median progression-free survival (PFS) after the second-line therapy and median overall survival were 21.6 months and 35.6 months, respectively. ASCT after the second line treatment (HR = 0.24) was an independent predictor of PFS. Eligible patients with primary refractory MM achieve the most benefit from ASCT, also performed immediately after first line induction therapy.

引用

页码：2868 / 2875

页数：8

共 35 条

[1] IMWG consensus on risk stratification in multiple myeloma [J].

Chng, W. J. ;

Dispenzieri, A. ;

Chim, C-S ;

Fonseca, R. ;

Goldschmidt, H. ;

Lentzsch, S. ;

Munshi, N. ;

Palumbo, A. ;

Miguel, J. S. ;

Sonneveld, P. ;

Cavo, M. ;

Usmani, S. ;

Durie, B. G. M. ;

Avet-Loiseau, H. .

LEUKEMIA, 2014, 28 (02) :269-277

[2] Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study [J].

Cohen, Yael C. ;

Saranga, Avi ;

Gatt, Moshe E. ;

Lavi, Noa ;

Ganzel, Chezi ;

Magen, Hila ;

Avivi, Irit ;

Tadmor, Tamar ;

Suriu, Celia ;

Dolberg, Osnat Jarchowsky ;

Papushado, Amitai ;

Trestman, Svetlana ;

Ram, Ron .

AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (06) :810-815

[3] Primary failure of bortezomib in newly diagnosed multiple myeloma - understanding the magnitude, predictors, and significance [J].

Cohen, Yael C. ;

Joffe, Erel ;

Benyamini, Noam ;

Dimopoulos, Meletios A. ;

Terpos, Evangelos ;

Trestman, Svetlana ;

Held-Kuznetsov, Viki ;

Avivi, Irit ;

Kastritis, Efstathios .

LEUKEMIA & LYMPHOMA, 2016, 57 (06) :1382-1388

[4]

Dhakal Binod, 2016, F1000Res, V5, DOI 10.12688/f1000research.8777.1

[5] Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma [J].

Dimopoulos, M. A. ;

Oriol, A. ;

Nahi, H. ;

San-Miguel, J. ;

Bahlis, N. J. ;

Usmani, S. Z. ;

Rabin, N. ;

Orlowski, R. Z. ;

Komarnicki, M. ;

Suzuki, K. ;

Plesner, T. ;

Yoon, S. -S. ;

Ben Yehuda, D. ;

Richardson, P. G. ;

Goldschmidt, H. ;

Reece, D. ;

Lisby, S. ;

Khokhar, N. Z. ;

O'Rourke, L. ;

Chiu, C. ;

Qin, X. ;

Guckert, M. ;

Ahmadi, T. ;

Moreau, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (14) :1319-1331

[6] Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study [J].

Dimopoulos, Meletios A. ;

Moreau, Philippe ;

Palumbo, Antonio ;

Joshua, Douglas ;

Pour, Ludek ;

Hajek, Roman ;

Facon, Thierry ;

Ludwig, Heinz ;

Oriol, Albert ;

Goldschmidt, Hartmut ;

Rosinol, Laura ;

Straub, Jan ;

Suvorov, Aleksandr ;

Araujo, Carla ;

Rimashevskaya, Elena ;

Pika, Tomas ;

Gaidano, Gianluca ;

Weisel, Katja ;

Goranova-Marinova, Vesselina ;

Schwarer, Anthony ;

Minuk, Leonard ;

Masszi, Tamas ;

Karamanesht, Ievgenii ;

Offidani, Massimo ;

Hungria, Vania ;

Spencer, Andrew ;

Orlowski, Robert Z. ;

Gillenwater, Heidi H. ;

Mohamed, Nehal ;

Feng, Shibao ;

Chng, Wee-Joo .

LANCET ONCOLOGY, 2016, 17 (01) :27-38

[7] International uniform response criteria for multiple myeloma [J].

Durie, B. G. M. ;

Harousseau, J-L ;

Miguel, J. S. ;

Blade, J. ;

Barlogie, B. ;

Anderson, K. ;

Gertz, M. ;

Dimopoulos, M. ;

Westin, J. ;

Sonneveld, P. ;

Ludwig, H. ;

Gahrton, G. ;

Beksac, M. ;

Crowley, J. ;

Belch, A. ;

Boccadaro, M. ;

Turesson, I. ;

Joshua, D. ;

Vesole, D. ;

Kyle, R. ;

Alexanian, R. ;

Tricot, G. ;

Attal, M. ;

Merlini, G. ;

Powles, R. ;

Richardson, P. ;

Shimizu, K. ;

Tosi, P. ;

Morgan, G. ;

Rajkumar, S. V. .

LEUKEMIA, 2006, 20 (09) :1467-1473

[8] Trends in overall survival and costs of multiple myeloma, 2000-2014 [J].

Fonseca, R. ;

Abouzaid, S. ;

Bonafede, M. ;

Cai, Q. ;

Parikh, K. ;

Cosler, L. ;

Richardson, P. .

LEUKEMIA, 2017, 31 (09) :1915-1921

[9] Management of induction failures in newly diagnosed transplant-eligible multiple myeloma [J].

Gertz, Morie A. .

LEUKEMIA & LYMPHOMA, 2020, 61 (01) :1-3

[10] Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction [J].

Gertz, Morie A. ;

Kumar, Shaji ;

Lacy, Martha Q. ;

Dispenzieri, Angela ;

Dingli, David ;

Hayman, Suzanne R. ;

Buadi, Francis K. ;

Hogan, William J. .

BLOOD, 2010, 115 (12) :2348-2353

← 1 2 3 4 →